Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Lumos Pharma Inc (NQ: LUMO )

4.095 +0.045 (+1.11%)
Streaming Delayed Price Updated: 9:46 AM EDT, Aug 29, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Lumos Pharma Inc

< Previous 1 2 3 4 Next >
Lumos Pharma to Participate in H.C. Wainwright 26th Annual Global Investment Conference
From Lumos Pharma, Inc.
Via GlobeNewswire
Lumos Pharma Reports Second Quarter 2024 Financial Results and Provides Clinical Development Update
From Lumos Pharma, Inc.
Via GlobeNewswire
Lumos Pharma to Report Second Quarter 2024 Financial Results and Provide Clinical Update on August 1, 2024
From Lumos Pharma, Inc.
Via GlobeNewswire
Lumos Pharma: Q4 Earnings Insights
Via Benzinga
Earnings Preview: Lumos Pharma
Via Benzinga
Lumos Pharma Announces New Analyses of Phase 2 OraGrowtH212 Trial Presented at ENDO 2024
From Lumos Pharma, Inc.
Via GlobeNewswire
Lumos Pharma Announces Abstracts Accepted for Presentation at ENDO 2024
From Lumos Pharma, Inc.
Via GlobeNewswire
LUMO Stock Earnings: Lumos Pharma Misses EPS, Misses Revenue for Q1 2024
LUMO stock results show that Lumos Pharma missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024. 
Via InvestorPlace
Lumos Pharma Announces Positive End-of-Phase 2 Meeting with FDA and Reports First Quarter 2024 Financial Results
From Lumos Pharma, Inc.
Via GlobeNewswire
Lumos Pharma to Report First Quarter 2024 Financial Results and Provide Clinical Update on May 15, 2024
From Lumos Pharma, Inc.
Via GlobeNewswire
Lumos Pharma Announces Abstracts Accepted for Presentation at Upcoming Medical Meetings
From Lumos Pharma, Inc.
Via GlobeNewswire
BioMedNewsBreaks – Lumos Pharma Inc. (NASDAQ: LUMO) Receives Patent Notice for Improved Formulation of Lead Therapeutic Candidate
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
Lumos Pharma Announces that the USPTO Has Granted Patent Protection for Novel Formulation of LUM-201, Extending Exclusivity to 2042
From Lumos Pharma, Inc.
Via GlobeNewswire
LUMO Stock Earnings: Lumos Pharma Misses EPS for Q4 2023
LUMO stock results show that Lumos Pharma missed analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
Lumos Pharma Reports Full Year 2023 Financial Results and Provides Clinical Development Update
From Lumos Pharma, Inc.
Via GlobeNewswire
Lumos Pharma to Report Full Year 2023 Financial Results and Host Conference Call on March 7, 2024
From Lumos Pharma, Inc.
Via GlobeNewswire
Lumos Pharma to Participate in Oppenheimer’s 34th Annual Healthcare Life Sciences Conference
From Lumos Pharma, Inc.
Via GlobeNewswire
Earnings Scheduled For March 7, 2024
Companies Reporting Before The Bell • CI&T (NYSE:CINT) is estimated to report quarterly earnings at $0.06 per share on revenue of $106.08 million. 
Via Benzinga
Lumos Pharma Promotes Pisit “Duke” Pitukcheewanont, MD to Chief Medical Officer
From Lumos Pharma, Inc.
Via GlobeNewswire
Lumos Pharma to Host Virtual Key Opinion Leader Webinar to Discuss Phase 2 OraGrowtH Trial Data and Treatment Potential of Oral LUM-201 for Pediatric Growth Hormone Deficiency
Webinar to be Held December 6, 2023 at 1:30pm EST 
From Lumos Pharma, Inc.
Via GlobeNewswire
Lumos Pharma Announces Participation in the Piper Sandler 35th Annual Healthcare Conference in November
From Lumos Pharma, Inc.
Via GlobeNewswire
Why Toast Shares Are Trading Lower By Around 17%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Gainers Heart Test Laboratories, Inc. (NASDAQ: HSCS) shares climbed 96% to $0.2921 after falling over 7% on Tuesday. 
Via Benzinga
Why Is Biomarin & BridgeBio Pharma Rival Lumos Pharma Stock Trading Higher Today?
Lumos Pharma Inc (NASDAQ: LUMO) announced that topline results from its Phase 2 OraGrowtH210 dose-finding trial and its Phase 2 OraGrowtH212 Pharmacokinetic/Pharmacodynamic (PK/PD) trial met all... 
Via Benzinga
Roblox, Under Armour, GoPro, Nuvei And Other Big Stocks Moving Higher On Wednesday
U.S. stocks traded mostly lower, with the Nasdaq Composite falling around 20 points on Wednesday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Topics Stocks
Exposures US Equities
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Why American Public Education Shares Are Trading Higher By Around 21%; Here Are 20 Stocks Moving Premarket
Gainers Heart Test Laboratories, Inc. (NASDAQ: HSCS) shares surged 332% to $0.6455 in pre-market trading after falling over 7% on Tuesday. 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Pre-market stock movers are a hot topic on Wednesday and we're starting the morning with a breakdown of the biggest ones. 
Via InvestorPlace
Lumos Pharma Reports Third Quarter 2023 Financial Results and Clinical Development Updates
From Lumos Pharma, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
Lumos Pharma Announces Topline Data from Phase 2 OraGrowtH210 and OraGrowtH212 Trials of LUM-201 in PGHD Met All Primary and Secondary Endpoints
Phase 2 Data Provide Supportive Evidence to Advance Oral LUM-201 to Phase 3 
From Lumos Pharma, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.